Research programme: cancer theraputics - Onchilles Pharma
Latest Information Update: 25 Jun 2021
At a glance
- Originator Onchilles Pharma
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer